Involvement of the CA1 GABAA receptors in MK-801-induced anxiolytic-like effects: An isobologram analysis

Behavioural Pharmacology

Volumn 25, Issue 3, 2014, Pages 197-205

  Naseri, Mohammad Hasan ^a,b   Hesami Tackallou, Saeed ^d   Torabi Nami, Mohammad ^e   Zarrindast, Mohammad Reza ^c   Nasehi, Mohammad ^d  

^a ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anxiolytic like effects; bicuculline; CA1; elevated plus maze; muscimol; rat

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BICUCULLINE; DIZOCILPINE; MUSCIMOL; ANXIOLYTIC AGENT; DIZOCILPINE MALEATE; GABAERGIC RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; HIPPOCAMPAL CA1 REGION; MALE; NONHUMAN; RAT; TRANQUILIZING ACTIVITY; ANALYSIS OF VARIANCE; ANIMAL; ANXIETY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG THERAPY; MAZE TEST; METABOLISM; MICROINJECTION; PATHOLOGY; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BICUCULLINE; CA1 REGION, HIPPOCAMPAL; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA AGENTS; MALE; MAZE LEARNING; MICROINJECTIONS; MUSCIMOL; RATS; RATS, WISTAR; RECEPTORS, GABA-A;

EID: 84899945524     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000037     Document Type: Article

References (81)

1. Ahmadi H, Nasehi M, Rostami P, Zarrindast MR (2013). Involvement of the nucleus accumbens shell dopaminergic system in prelimbic NMDA-induced anxiolytic-like behaviors. Neuropharmacology 71:112-123.
2. Bak LK, Schousboe A, Waagepetersen HS (2006). The glutamate/GABAglutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 98:641-653.
3. Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawlins JNP, Bannerman DM (2009). Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur J Pharmacol 626:49-56.
4. Barros DM, Izquierdo LA, Mello e Souza T, Ardenghi PG, Pereira P, Medina JH, et al. (2000). Molecular signalling pathways in the cerebral cortex are required for retrieval of one-trial avoidance learning in rats. Behav Brain Res 114:183-192.
5. Bergink V, van Megen HJ, Westenberg HG (2004). Glutamate and anxiety. Eur Neuropsychopharmacol 14:175-183.
6. Blackstad TW, Kjaerheim A (1961). Special axo-dendritic synapses in the hippocampal cortex: electron and light microscopic studies on the layer of mossy fibers. J Comp Neurol 117:133-159.
7. Boyce-Rustay JM, Holmes A (2006). Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressant-like effects in mice. Neuropsychopharmacology 31:2405-2414.
8. Chojnacka-Wojcik E, Klodzinska A, Pilc A (2001). Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs 2:1112-1119.
9. Cortese BM, Phan KL (2005). The role of glutamate in anxiety and related disorders. CNS Spectr 10:820-830.
10. Crestani F, Lorez M, Baer K, Essrich C, Benke D, Laurent JP, et al. (1999). Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat Neurosci 2:833-839.
11. Degroot A, Treit D. 2004, Anxiety is functionally segregated within the septohippocampal system. Brain Res, 1001, 60-71
12. Degroot A, Treit D (2004). Anxiety is functionally segregated within the septohippocampal system. Brain Res 1001:60-71.Dinan T (2006). Therapeutic options: addressing the current dilemma. Eur Neuropsychopharmacol 16 (Suppl 2):S119-S127.
13. Gault LM, Siegel RE (1998). NMDA receptor stimulation selectively initiates GABA(A) receptor delta subunit mRNA expression in cultured rat cerebellar granule neurons. J Neurochem 70:1907-1915.
14. Golembiowska K, Dziubina A (2000). Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol 52:441-448.
15. Greene R (2001). Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11:569-577.
16. Hargreaves EL, Cain DP (1992). Hyperactivity, hyper-reactivity, and sensorimotor deficits induced by low doses of the N-methyl-D-aspartate non-competitive channel blocker MK801. Behav Brain Res 47:23-33.
17. Harris BT, Charlton ME, Costa E, Grayson DR (1994). Quantitative changes in alpha 1 and alpha 5 gamma-aminobutyric acid type A receptor subunit mRNAs and proteins after a single treatment of cerebellar granule neurons with N-methyl-D-aspartate. Mol Pharmacol 45:637-648.
18. Harvey BH, Shahid M (2012). Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models. Pharmacol Biochem Behav 100:775-800.
19. Inoue M, Oomura Y, Yakushiji T, Akaike N (1986). Intracellular calcium ions decrease the affinity of the GABA receptor. Nature 324:156-158.
20. Izquierdo I, Medina JH (1997). Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem 68:285-316.
21. Jamali-Raeufy N, Nasehi M, Zarrindast MR (2011). Influence of N-methyl Daspartate receptor mechanism on WIN55,212-2-induced amnesia in rat dorsal hippocampus. Behav Pharmacol 22:645-654.
22. Kalueff A, Nutt DJ (1997). Role of GABA in memory and anxiety. Depress Anxiety 4:100-110.
23. Karcz-Kubicha M, Liljequist S (1995). Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Eur J Pharmacol 279: 171-177.
24. Kent JM, Mathew SJ, Gorman JM (2002). Molecular targets in the treatment of anxiety. Biol Psychiatry 52:1008-1030.
25. Kim HS, Choi HS, Lee SY, Oh S (2000). Changes of GABA(A) receptor binding and subunit mRNA level in rat brain by infusion of subtoxic dose of MK-801. Brain Res 880:28-37.
26. Kumar K, Sharma S, Kumar P, Deshmukh R (2013). Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders. Pharmacol Biochem Behav 110:174-184.
27. Lim AL, Taylor DA, Malone DT (2012). Consequences of early life MK-801 administration: long-term behavioural effects and relevance to schizophrenia research. Behav Brain Res 227:276-286.
28. Llano I, Leresche N, Marty A (1991). Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synapticcurrents. Neuron 6:565-574.
29. Long P, Mercer A, Begum R, Stephens GJ, Sihra TS, Jovanovic JN (2009). Nerve terminal GABAA receptors activate Ca2+/calmodulin-dependent signaling to inhibit voltage-gated Ca2+ influx and glutamate release. J Biol Chem 284:8726-8737.
30. Lu Y,Wehner JM (1997). Enhancement of contextual fear-conditioning by putative (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate (NMDA) receptor antagonists in DBA/2J mice. Brain Res 768:197-207.
31. Lyne J, Kelly BD, O'Connor WT (2004). Schizophrenia: a review of neuropharmacology. Ir J Med Sci 173:155-159.
32. Malizia AL (1999). What do brain imaging studies tell us about anxiety disorders? J Psychopharmacol 13:372-378.
33. Matheus MG, Guimaraes FS (1997). Antagonism of non-NMDA receptors in the ndorsal periaqueductal grey induces anxiolytic effect in the elevated plus maze. Psychopharmacology (Berl) 132:14-18.
34. Matthews DB, Kralic JE, Devaud LL, Fritschy JM, Marrow AL (2000). Chronic blockade of N-methyl-D-aspartate receptors alters gamma-aminobutyric acid type A receptor peptide expression and function in the rat. J Neurochem 74:1522-1528.
35. McNaughton N, Gray JA (2000). Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 61:161-176.
36. Meldrum BS (1994). The role of glutamate in epilepsy and other CNS disorders. Neurology 44 (Suppl 8):S14-S23.
37. Mohler H, Fritschy JM, Vogt K, Crestani F, Rudolph U (2005). Pathophysiology and pharmacology of GABA(A) receptors. Handb Exp Pharmacol 169: 225-247.
38. Mohler H (2012). The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 62:42-53.
39. Mohr C, Schneider S (2013). Anxiety disorders. Eur Child Adolesc Psychiatry 22 (Suppl 1):S17-S22.
40. Morrow AL (1995). Regulation of GABAA receptor function and gene expression in the central nervous system. Int Rev Neurobiol 38:1-41.
41. Mouginot D, Feltz P, Schlichter R (1991). Modulation of GABA-gated chloride currents by intracellular Ca2+ in cultured porcine melanotrophs. J Physiol 437:109-132.
42. Nascimento Hackl LP, Carobrez AP (2007). Distinct ventral and dorsal hippocampus AP5 anxiolytic effects revealed in the elevated plus-maze task in rats. Neurobiol Learn Mem 88:177-185.
43. Oh S, Ho IK (1999). Changes of [3H]muscimol binding and GABA(A) receptor beta2-subunit mRNA level by tolerance to and withdrawal from pentobarbital in rats. Neurochem Res 24:1603-1609.
44. Ohkuma S, Chen SH, Katsura M, Chen DZ, Kuriyama K (1994). Muscimol prevents neuronal injury induced by NMDA. Jpn J Pharmacol 64:125-128.
45. Olivier JD, Vinkers CH, Olivier B (2013). The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders. Front Pharmacol 4:74.
46. Olsen RW, Sieghart W (2009). GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56:141-148.
47. Padovan CM, Guimaraes FS (2000). Restraint-induced hypoactivity in an elevated plus-maze. Braz J Med Biol Res 33:79-83.
48. Paxinos G, Watson C (2007). The rat brain in stereotaxic coordinates. 6th ed. London, UK: Academic Press.
49. Plaznik A, Palejko W, Nazar M, Jessa M (1994). Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 4:503-512.
50. Rapp A, Dodds A, Walkup JT, Rynn M (2013). Treatment of pediatric anxiety disorders. Ann N Y Acad Sci 1304:52-61.
51. Rezayat M, Roohbakhsh A, Zarrindast MR, Massoudi R, Djahanguiri B (2005). Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol Behav 84:775-782.
52. Rezvanfard M, Zarrindast MR, Bina P (2009). Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test. Pharmacology 84:356-366.
53. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E (2012). New perspectives in glutamate and anxiety. Pharmacol Biochem Behav 100:752-774.
54. Robinson MB (2006). Acute regulation of sodium-dependent glutamate transporters: a focus on constitutive and regulated trafficking. Handb Exp Pharmacol 175:251-275.
55. Rostami P, Hajizadeh-Moghaddam A, Zarrindast MR (2006). The effects of histaminergic agents in the ventral hippocampus of rats in the plus-maze test of anxiety-like behaviours. Physiol Behav 87:891-896.
56. Sahai S (1990). Glutamate in the mammalian CNS. Eur Arch Psychiatry Clin Neurosci 240:121-133.
57. Somogyi J, Baude A, Omori Y, Shimizu H, El Mestikawy S, Fukaya M, et al. (2004). GABAergic basket cells expressing cholecystokinin contain vesicular glutamate transporter type 3 (VGLUT3) in their synaptic terminals in hippocampus and isocortex of the rat. Eur J Neurosci 19:552-569.
58. Stelzer A, Shi H (1994). Impairment of GABAA receptor function by N-methyl-Daspartate-mediated calcium influx in isolated CA1 pyramidal cells. Neuroscience 62:813-828.
59. Svensson TH (2000). Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 31:320-329.
60. Swain J, Hancock K, Hainsworth C, Bowman J (2013). Acceptance and commitment therapy in the treatment of anxiety: a systematic review. Clin Psychol Rev 33:965-978.
61. Swanson LW, Cowan WM, 1977, An autoradiographic study of the organization of the efferent connections of the hippocampal formation in the rat. J Comp Neurol. 172, 49-84
62. Swanson LW, Cowan WM (1977). An autoradiographic study of the organization of the efferent connections of the hippocampal formation in the rat. J Comp Neurol 172:49-84.
63. Tallarida RJ, Porreca F, Cowan A (1989). Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci 45:947-961.
64. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, et al. (1999). Genetic enhancement of learning and memory in mice. Nature 401:63-69.
65. Thornberg SA, Saklad SR (1996). A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 16:82-93.
66. Tokarski K, Bobula B, Wabno J, Hess G (2008). Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 153:789-795.
67. Tsai G, Coyle JT (2002). Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
68. Tsien JZ, Huerta PT,Tonegawa S (1996). The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 87:1327-1338.
69. Vaidya A, Jain S, Jain AK, Agrawal A, Kashaw SK, Jain SK, et al. (2013). Metabotropic glutamate receptors: a review on prospectives and therapeuticaspects. Mini Rev Med Chem 13:1967-1981.
70. Wang XH, Zhu WJ, Corsi L, Ikonomovic S, Paljug WR, Vicini S, et al. (1998). Chronic dizocilpine (MK-801) reversibly delays GABA(A) receptor maturation in cerebellar granule neurons in vitro. J Neurochem 71:693-704.
71. Wieronska JM, Pilc A (2009). Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 55:85-97.
72. Wyss JM, Swanson LW, Cowan WM (1980). The organization of the fimbria,dorsal fornix and ventral hippocampal commissure in the rat. Anat Embryol(Berl) 158:303-316.
73. Yousefi B, Farjad M, Nasehi M, Zarrindast MR (2013). Involvement of the CA1GABAA receptors in ACPA-induced impairment of spatial and non-spatialnovelty detection in mice. Neurobiol Learn Mem 100:32-40.
74. Zarate CA Jr, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, et al. (2003).Regulation of cellular plasticity cascades in the pathophysiology and treatmentof mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 1003:273-291.
75. Zarrindast MR, Bakhsha A, Rostami P, Shafaghi B (2002). Effects ofintrahippocampal injection of GABAergic drugs on memory retention ofpassive avoidance learning in rats. J Psychopharmacol 16:313-319.
76. Zarrindast MR, Torabi M, Rostami P, Fazli-Tabaei S (2006). The effects ofhistaminergic agents in the dorsal hippocampus of rats in the elevated plusmazetest of anxiety. Pharmacol Biochem Behav 85:500-506.
77. Zarrindast MR, Nasehi M, Khansari M, Bananej M (2010). Influence of nitric oxideagents in the rat amygdala on anxiogenic-like effect induced by histamine.Neurosci Lett 489:38-42.
78. Zarrindast MR, Nasehi M, Piri M, Heidari N (2011). Effects of cholinergic systemof dorsal hippocampus of rats on MK-801 induced anxiolytic-like behavior.Neurosci Lett 505:65-70.
79. Zarrindast MR, Nasehi M, Pournaghshband M, Yekta BG (2012). Dopaminergicsystem in CA1 modulates MK-801 induced anxiolytic-like responses.Pharmacol Biochem Behav 103:102-110.
80. Zhang J,Wu D, Xie C,Wang H,Wang W, Zhang H, et al. (2013). Tramadol andpropentofylline coadministration exerted synergistic effects on rat spinalnerve ligation-induced neuropathic pain. PloS One 8:e72943.
81. Zhu WJ, Vicini S, Harris BT, Grayson DR (1995). NMDA-mediated modulation ofgamma-aminobutyric acid type A receptor function in cerebellar granuleneurons. J Neurosci 15:7692-7701.